Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer. The trial showed consistent benefits across clinical endpoints, ...
An expert discusses how the greatest unmet need in minimally invasive benign prostatic hyperplasia (BPH) treatments is achieving durability and retreatment rates that match those of surgical options ...
Muhammed A. Moukhtar Hammad, MBBCh, outlines key findings from a study evaluating testosterone replacement therapy and hearing-related outcomes. Testosterone therapy was not associated with an ...
Krambeck highlights that FANS combine enhanced maneuverability and effective fragment evacuation, leading to higher stone clearance rates and improved procedural outcomes in endourology. In this video ...
The ARASAFE study showed significant reductions in grade 3-5 adverse events and grade 3-4 neutropenia or death with a 50 mg/m2 docetaxel regimen. Despite a higher cumulative docetaxel dose, the 50 ...
Aleece Fosnight, MSPAS, PA-C, highlights that although urinary leakage is common, it is not normal—and effective treatment options exist. In this interview, Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback